Accelerating DoD’s Fielding of Prototypes for Medical Countermeasures
June 16th BIO International Convention
June 13-16
San Diego, CA
subdirectory_arrow_rightTherapeutic Medical Countermeasure Strategies for
Addressing Emerging Bacterial Threats
subdirectory_arrow_right ReVAMP: ReinVigorating Abandoned AntiMicrobial Products
New Draft RPPs Released:
None at this time
New RFIs Released:
None at this time
MCDC2207: Needle-Free Vaccine Delivery Platform Prototypes
MCDC2206: Vaccine Encapsulation Prototype
MCDC2205: Adjuvant Activity to Vaccines Prototype
Non-Traditional Members
The Medical CBRN Defense Consortium (MCDC) was formed in response to the Government’s expressed interest to establish an Other Transaction Agreement (OTA) with an eligible entity or group of entities, to include industry, academic, and not-for-profit partners, for advanced development efforts to support the Department of Defense’s (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.
WHO CAN JOIN
Companies that are part of the US Industrial base, as well as new and emerging non-traditional defense contractors, are encouraged to join the MCDC and participate in Federally-funded R&D projects.
- Traditional Contractors
- Non-Traditionals (Companies that don’t typically participate in Federal R&D)
- Academia
- Non-Profit/ Not-For-Profit Research Institutions
Led by
MCDC research and prototype work is executed by project teams from a broad-based industry/ academia collaboration.
Sponsored by
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense
Managed by
Collaboration Management Firm Advanced Technology International (ATI)